Hagerman PJ: The fragile X prevalence paradox. J Med Genet 2008, 45(8):498–499. 10.1136/jmg.2008.059055
Article
Google Scholar
Fragile X syndrome: diagnosis, treatment, and research. John Hopkins University Press, Baltimore; 2002.
Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 2004, 27(7):370–377. 10.1016/j.tins.2004.04.009
Article
CAS
Google Scholar
Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK: Outcome measures for clinical trials in fragile x syndrome. J Dev Behav Pediatr 2013, 34(7):508–522. 10.1097/DBP.0b013e31829d1f20
Article
Google Scholar
Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D: Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2012, 42(7):1377–1392. 10.1007/s10803-011-1370-2
Article
Google Scholar
Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ: Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase trial. Sci Transl Med 2012, 4(152):127. 10.1126/scitranslmed.3004214
Article
Google Scholar
Wang X, Snape M, Klann E, Stone JG, Singh A, Petersen RB, Castellani RJ, Casadesus G, Smith MA, Zhu X: Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile X-syndrome. J Neurochem 2012, 121(4):672–679. 10.1111/j.1471-4159.2012.07722.x
Article
CAS
Google Scholar
Weng N, Weiler IJ, Sumis A, Berry-Kravis E, Greenough WT: Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet 2008, 147B(7):1253–1257. 10.1002/ajmg.b.30765
Article
CAS
Google Scholar
Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT: Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008, 29(4):293–302. 10.1097/DBP.0b013e31817dc447
Article
Google Scholar
Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ: Open-label riluzole in fragile X syndrome. Brain Res 2011, 1380: 264–270. 10.1016/j.brainres.2010.10.108
Article
CAS
Google Scholar
Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS: Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010, 30(2):694–702. 10.1523/JNEUROSCI.3696-09.2010
Article
CAS
Google Scholar
Gross C, Bassell GJ: Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol Med 2012, 18: 336–345. 10.2119/molmed.2011.00363
Article
CAS
Google Scholar
Janusz A, Milek J, Perycz M, Pacini L, Bagni C, Kaczmarek L, Dziembowska M: The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J Neurosci 2013, 33(46):18234–18241. 10.1523/JNEUROSCI.2207-13.2013
Article
CAS
Google Scholar
Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM: Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J Med Genet 2009, 46(2):94–102. 10.1136/jmg.2008.061796
Article
CAS
Google Scholar
Siller SS, Broadie K: Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast 2012, 2012: 124548.
Google Scholar
Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW: Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010, 10: 91. 10.1186/1471-2377-10-91
Article
Google Scholar
Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ: A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr 2013, 34(3):147–155. 10.1097/DBP.0b013e318287cd17
Article
Google Scholar
Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, Durbin-Johnson B, Hagerman RJ, Tassone F: High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A 2013, 161A(8):1897–1903. 10.1002/ajmg.a.36023
Article
Google Scholar
Westmark CJ, Malter JS: FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol 2007, 5(3):e52. 10.1371/journal.pbio.0050052
Article
Google Scholar
Westmark CJ, Westmark PR, O’Riordan KJ, Ray BC, Hervey CM, Salamat MS, Abozeid SH, Stein KM, Stodola LA, Tranfaglia M, Burger C, Berry-Kravis EM, Malter JS: Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 2011, 6(10):e26549. 10.1371/journal.pone.0026549
Article
CAS
Google Scholar
Ray B, Long JM, Sokol DK, Lahiri DK: Increased secreted amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 2011, 6(6):e20405. 10.1371/journal.pone.0020405
Article
CAS
Google Scholar
Westmark CJ, Hervey CM, Berry-Kravis EM, Malter JS: Effect of anticoagulants on amyloid beta-protein precursor and amyloid beta levels in plasma. Alzheimer's Disease and Parkinsonism 2011, 1(1):1–3.
Google Scholar
Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ: Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013, 228(1):75–84. 10.1007/s00213-013-3022-z
Article
CAS
Google Scholar
Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F: Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with Fragile X syndrome. Genes Brain Behav 2012, 11(3):332–341. 10.1111/j.1601-183X.2012.00768.x
Article
CAS
Google Scholar
Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F: Plasma cytokine profiles in fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav Immun 2010, 24(6):898–902. 10.1016/j.bbi.2010.01.008
Article
CAS
Google Scholar